Contineum Therapeutics (CTNM) News Today $12.44 -0.04 (-0.32%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Royal Bank of Canada Reiterates "Outperform" Rating for Contineum Therapeutics (NASDAQ:CTNM)January 12, 2025 | americanbankingnews.comContineum Therapeutics' (CTNM) Outperform Rating Reiterated at Royal Bank of CanadaRoyal Bank of Canada reissued an "outperform" rating and set a $31.00 price target on shares of Contineum Therapeutics in a report on Thursday.January 9, 2025 | marketbeat.comContineum Therapeutics Completes Enrollment in Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)January 8, 2025 | businesswire.comContineum Therapeutics, Inc. (NASDAQ:CTNM) Short Interest UpdateContineum Therapeutics, Inc. (NASDAQ:CTNM - Get Free Report) was the target of a significant decrease in short interest during the month of December. As of December 15th, there was short interest totalling 983,600 shares, a decrease of 5.4% from the November 30th total of 1,040,000 shares. Based on an average daily volume of 99,500 shares, the days-to-cover ratio is presently 9.9 days. Currently, 7.0% of the shares of the stock are short sold.January 1, 2025 | marketbeat.comFranklin Resources Inc. Buys 820,542 Shares of Contineum Therapeutics, Inc. (NASDAQ:CTNM)Franklin Resources Inc. raised its stake in Contineum Therapeutics, Inc. (NASDAQ:CTNM - Free Report) by 130.9% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,447,550 shares of the company's stock aftDecember 19, 2024 | marketbeat.comContineum initiates patient dosing in Phase 1B PET trialDecember 18, 2024 | markets.businessinsider.comContineum Therapeutics Initiates Patient Dosing in Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791December 16, 2024 | finance.yahoo.comContineum Therapeutics Inc Class A Common StockDecember 11, 2024 | morningstar.comFmr LLC Buys 373,327 Shares of Contineum Therapeutics, Inc. (NASDAQ:CTNM)Fmr LLC grew its holdings in Contineum Therapeutics, Inc. (NASDAQ:CTNM - Free Report) by 115.4% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 696,927 shares of the company's stock after acquiring an aDecember 11, 2024 | marketbeat.comSuvretta Capital Management LLC Sells 333,334 Shares of Contineum Therapeutics, Inc. (NASDAQ:CTNM)Suvretta Capital Management LLC reduced its position in Contineum Therapeutics, Inc. (NASDAQ:CTNM - Free Report) by 16.2% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 1,720,000 shares of the company's stock after selling 333,334 shares during the period. SuvrNovember 29, 2024 | marketbeat.comContineum Therapeutics, Inc. (CTNM)November 28, 2024 | finance.yahoo.comContineum Therapeutics: Q3 2024 Financial OverviewNovember 25, 2024 | tipranks.comContineum Therapeutics to Attend the 7th Annual Evercore HealthCONx ConferenceNovember 25, 2024 | finance.yahoo.comContineum Therapeutics to Attend the 7th Annual Evercore HealthCONx ConferenceNovember 25, 2024 | businesswire.comContineum announces FDA authorization for PIPE-791November 19, 2024 | markets.businessinsider.comContineum Therapeutics Expands Clinical Development of PIPE-791 With FDA Authorization of Its Investigational New Drug (IND) Application for Chronic PainNovember 19, 2024 | businesswire.comHere's Why We're Not At All Concerned With Contineum Therapeutics' (NASDAQ:CTNM) Cash Burn SituationNovember 14, 2024 | finance.yahoo.comContineum Therapeutics to Attend Upcoming Investor ConferencesNovember 13, 2024 | businesswire.comContineum Therapeutics, Inc. Class A (CTNM) Receives a Buy from Stifel NicolausNovember 9, 2024 | markets.businessinsider.comContineum Therapeutics (NASDAQ:CTNM) Issues Quarterly Earnings ResultsContineum Therapeutics (NASDAQ:CTNM - Get Free Report) posted its earnings results on Wednesday. The company reported ($0.40) earnings per share for the quarter, beating the consensus estimate of ($0.41) by $0.01.November 9, 2024 | marketbeat.comRoyal Bank of Canada Cuts Contineum Therapeutics (NASDAQ:CTNM) Price Target to $31.00Royal Bank of Canada reduced their target price on Contineum Therapeutics from $32.00 to $31.00 and set an "outperform" rating for the company in a research note on Thursday.November 7, 2024 | marketbeat.comContineum Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business HighlightsNovember 6, 2024 | businesswire.comContineum initiated with an Outperform at BairdOctober 23, 2024 | markets.businessinsider.comPromising Prospects and Strong Financials Bolster Buy Rating for Contineum TherapeuticsOctober 23, 2024 | markets.businessinsider.comContineum Therapeutics (NASDAQ:CTNM) Rating Increased to Strong-Buy at Baird R WBaird R W upgraded shares of Contineum Therapeutics to a "strong-buy" rating in a research note on Tuesday.October 23, 2024 | marketbeat.comBaird Initiates Coverage of Contineum Therapeutics (CTNM) with Outperform RecommendationOctober 22, 2024 | msn.comContineum draws bullish view at Baird on de-risked assetsOctober 22, 2024 | msn.comContineum Therapeutics (NASDAQ:CTNM) Research Coverage Started at Robert W. BairdRobert W. Baird began coverage on Contineum Therapeutics in a report on Tuesday. They set an "outperform" rating and a $32.00 target price on the stock.October 22, 2024 | marketbeat.comContineum Therapeutics, Inc.'s (NASDAQ:CTNM) largest shareholders are individual investors with 41% ownership, institutions own 28%October 4, 2024 | finance.yahoo.comSquarepoint Ops LLC Invests $2.64 Million in Contineum Therapeutics, Inc. (NASDAQ:CTNM)Squarepoint Ops LLC bought a new position in shares of Contineum Therapeutics, Inc. (NASDAQ:CTNM - Free Report) in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund bought 150,000 shares of the company's stock, valuedOctober 3, 2024 | marketbeat.comIPO Roundup: FrontView REIT, StandardAero and moreSeptember 30, 2024 | msn.comPerceptive Advisors LLC Purchases Shares of 1,566,668 Contineum Therapeutics, Inc. (NASDAQ:CTNM)Perceptive Advisors LLC acquired a new position in Contineum Therapeutics, Inc. (NASDAQ:CTNM - Free Report) during the second quarter, according to its most recent 13F filing with the SEC. The firm acquired 1,566,668 shares of the company's stock, valued at approximately $27,589,000. Perceptive AdvSeptember 30, 2024 | marketbeat.comContineum Therapeutics, Inc.'s Lock-Up Period To End on October 2nd (NASDAQ:CTNM)Contineum Therapeutics' (NASDAQ:CTNM - Get Free Report) lock-up period will end on Wednesday, October 2nd. Contineum Therapeutics had issued 6,875,000 shares in its initial public offering on April 5th. The total size of the offering was $110,000,000 based on an initial share price of $16.00. After the end of the company's lock-up period, company insiders and major shareholders will be able to sell their shares of the company.September 25, 2024 | marketbeat.comContineum Therapeutics (NASDAQ:CTNM) Sees Large Volume IncreaseContineum Therapeutics (NASDAQ:CTNM) Sees Strong Trading VolumeSeptember 19, 2024 | marketbeat.comJohnson & Johnson Buys Shares of 1,979,173 Contineum Therapeutics, Inc. (NASDAQ:CTNM)Johnson & Johnson acquired a new position in Contineum Therapeutics, Inc. (NASDAQ:CTNM - Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 1,979,173 shares of the company's stock, valued at appSeptember 16, 2024 | marketbeat.comVersant Venture Management LLC Purchases Shares of 918,163 Contineum Therapeutics, Inc. (NASDAQ:CTNM)Versant Venture Management LLC purchased a new stake in Contineum Therapeutics, Inc. (NASDAQ:CTNM - Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 918,163 shares of the company's stock, valued at approximately $16,169,000. CoSeptember 11, 2024 | marketbeat.comContineum Therapeutics to Present at Multiple Upcoming Investor ConferencesAugust 28, 2024 | businesswire.comContineum Therapeutics (NASDAQ:CTNM) Trading Up 5.3%Contineum Therapeutics (NASDAQ:CTNM) Shares Up 5.3%August 16, 2024 | marketbeat.comRoyal Bank of Canada Raises Contineum Therapeutics (NASDAQ:CTNM) Price Target to $32.00Royal Bank of Canada boosted their target price on Contineum Therapeutics from $30.00 to $32.00 and gave the stock an "outperform" rating in a report on Wednesday.August 14, 2024 | marketbeat.comContineum Therapeutics (NASDAQ:CTNM) Releases Quarterly Earnings Results, Misses Expectations By $0.02 EPSContineum Therapeutics (NASDAQ:CTNM - Get Free Report) released its earnings results on Tuesday. The company reported ($0.39) EPS for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.02).August 14, 2024 | marketbeat.comContineum Therapeutics (NASDAQ:CTNM) Stock Price Down 6.1%Contineum Therapeutics (NASDAQ:CTNM) Shares Down 6.1%August 14, 2024 | marketbeat.comCTNM Stock Earnings: Contineum Therapeutics Misses EPS for Q2 2024August 13, 2024 | markets.businessinsider.comContineum Therapeutics (NASDAQ:CTNM) Trading Down 3%Contineum Therapeutics (NASDAQ:CTNM) Stock Price Down 3%July 9, 2024 | marketbeat.comContineum Therapeutics (NASDAQ:CTNM) Shares Down 3% Contineum Therapeutics (NASDAQ:CTNM) Stock Price Down 3%July 3, 2024 | marketbeat.comContineum Therapeutics (NASDAQ:CTNM) Stock Price Up 13.5%Contineum Therapeutics (NASDAQ:CTNM) Shares Up 13.5%July 1, 2024 | marketbeat.comContineum Therapeutics (NASDAQ:CTNM) Sets New 12-Month High at $20.97Contineum Therapeutics (NASDAQ:CTNM) Hits New 52-Week High at $20.97June 26, 2024 | marketbeat.comContineum Therapeutics (NASDAQ:CTNM) Hits New 1-Year High at $20.74Contineum Therapeutics (NASDAQ:CTNM) Hits New 12-Month High at $20.74June 20, 2024 | marketbeat.comContineum Therapeutics (NASDAQ:CTNM) Trading Up 19.1%Contineum Therapeutics (NASDAQ:CTNM) Shares Up 19.1%June 20, 2024 | marketbeat.comContineum: LPA1R Antagonist Drug Advancement Against IPF With Proven Track ModelJune 13, 2024 | seekingalpha.comStifel Nicolaus Sticks to Its Buy Rating for Contineum Therapeutics, Inc. Class A (CTNM)May 21, 2024 | markets.businessinsider.com Get Contineum Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CTNM and its competitors with MarketBeat's FREE daily newsletter. Email Address CTNM Media Mentions By Week CTNM Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CTNM News Sentiment▼0.000.44▲Average Medical News Sentiment CTNM News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CTNM Articles This Week▼01▲CTNM Articles Average Week Get Contineum Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CTNM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies NRIX News Today KNSA News Today RCUS News Today OCUL News Today MRVI News Today ARVN News Today PRAX News Today CALT News Today DAWN News Today ANIP News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CTNM) was last updated on 1/20/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMust-See: 5-Second Trump PredictionPresident Trump's prediction is about to become a reality... Opening a rare window of opportunity for you t...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredWarren Buffett Bets $40 Billion—You Can Get in for $20I call it "The Last Retirement Stock You'll Ever Need." Warren Buffett himself owns $40 billion of stock in...Behind the Markets | SponsoredKamala’s final humiliation The investments connected to Trump's second term in ways that almost nobody outside his inner circle is aware ...Porter & Company | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Contineum Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Contineum Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
